Pfizer Shares Fall 2.83% Amid Strategic Announcements
The American pharmaceutical giant Pfizer experienced a challenging session on Wall Street on Friday, with its stock falling 2.83% to $25.06. This decline occurred as the company is multiplying initiatives to restructure its portfolio and boost growth following the pandemic euphoria. Despite positive elements, the market seems to temper its enthusiasm in the face of short-term challenges.
Significant Market Movements on November 14
Pfizer's stock closed the day on November 14 at $25.06, down 2.83% compared to the previous session. This correction occurred in the context of significant trading volumes, with nearly 96.5 million shares exchanged, representing 1.7% of the group's capitalization. The stock thus experienced one of its most substantial negative fluctuations in recent months, highlighting the intensity of portfolio movements around this defensive value. For comparison, the S&P 500 index advanced by 0.36% over the same period, underlining the relative underperformance of the pharmaceutical stock. This contrast illustrates the sectoral divergences that continue to structure the markets. On a broader basis, Pfizer has shown a performance decrease of 3.69% over the past twelve months, while the S&P 500 has gained 18.33% over the same period, reflecting a notable divergence between technology stocks and so-called defensive sectors. This relative weakness of the laboratory contrasts, however, with the positive momentum recorded at the beginning of the year, where Pfizer had advanced by 2.58% over the week. The stock remains close to its 52-week high levels, established in October 2025 at $27.37.
Key Announcements on November 14
November 14 was marked by two major announcements that divided operators and largely explain the stock's correction. On one hand, Pfizer finalized its acquisition of Metsera, paying $65.60 per share in cash, complemented by a conditional consideration that could reach $20.65 per share depending on the achievement of clinical and regulatory milestones. This transaction, valued at approximately $7 billion excluding milestones, introduces assets in clinical phases in the fields of obesity and cardiometabolic disorders into the laboratory's portfolio. The acquired portfolio notably includes an injectable GLP-1 that can be administered weekly or monthly, prepared to enter phase 3 of clinical trials. On the other hand, Pfizer proceeded with a significant reduction in its stake in BioNTech, its historical partner, decreasing its stake from 54.7% to retain only 1.66 million shares, valued at approximately $163.5 million as of September 30. These two decisions reflect a resource allocation strategy aimed at rebuilding a weakened scientific pipeline after the end of the pandemic saga. The laboratory also announced targeting an additional $20 billion in revenue by 2030. However, the group warned that the acquisition of Metsera will be dilutive to earnings until 2030, which tempered the initial market reception. This expected dilution penalized the stock price, with some operators focusing on the short-term negative impact rather than the long-term promises. Concurrently, Scotiabank upgraded its recommendation on the stock during the same session, a gesture that reflects some analytical confidence despite the day's correction.
